HR5127

The PrEP and PEP are Prevention Act, H.R. 5127, mandates no-cost coverage for all FDA-approved HIV prevention drugs, including PrEP and PEP, and associated administrative fees, diagnostic procedures, counseling, and clinical follow-up. This is not a funding bill; it amends existing law (Public Health Service Act, Social Security Act, and U.S. Code Title 5) to require insurers to cover these services without cost-sharing. This creates a direct and immediate expansion of the market for these drugs and services by removing financial barriers for consumers, ensuring universal access and increasing utilization. The money trail for this legislation flows directly from health insurers to pharmaceutical companies and diagnostic service providers. Insurers must now cover these costs, which translates into increased revenue for drug manufacturers and diagnostic labs. The mechanism is a regulatory mandate on private insurance, Medicare, Medicaid, and federal employee health benefit plans. This guarantees a significant increase in the total addressable market for HIV prevention drugs and related diagnostics, as cost is no longer a barrier to access. Historically, similar mandates have led to increased utilization. For example, the Affordable Care Act (ACA) of 2010 mandated coverage for preventive services, leading to a measurable increase in screenings and vaccinations. While not directly comparable to a specific drug mandate, the principle of removing cost barriers to essential health services consistently drives demand. When the ACA was passed, health insurance stocks like $UNH and $ANTM (now part of $ELEVANCE HEALTH) saw initial volatility but ultimately adapted to new coverage requirements, often passing costs through premium adjustments over time. This bill, however, directly benefits specific drug and diagnostic companies. Specific winners include pharmaceutical companies manufacturing PrEP/PEP drugs. Gilead Sciences ($GILD) is a primary beneficiary as the developer of Truvada and Descovy, key PrEP medications. Viatris ($VTRS) also benefits from generic versions. Johnson & Johnson ($JNJ) and Merck ($MRK) have HIV treatment portfolios that could see indirect benefits from increased awareness and testing. Diagnostic providers like Abbott Laboratories ($ABT), Quest Diagnostics ($DGX), and LabCorp ($LH) will see increased demand for HIV diagnostic tests, viral load monitoring, and other related lab services. Health insurers, including UnitedHealth Group ($UNH), Elevance Health ($ELV), and Cigna ($CI), will face increased costs due to the mandated no-cost coverage, which they will likely attempt to offset through premium adjustments in subsequent years. The bill has significant legislative momentum, with 34 cosponsors and referral to three key committees, including Energy and Commerce and Ways and Means, indicating a strong likelihood of progression. This bill was introduced on September 4, 2025. The next steps involve committee hearings and markups. Given the strong sponsorship and policy area, it is likely to advance through the House and potentially the Senate. If enacted, the provisions would take effect as specified in the bill, likely within a year of passage, creating a sustained increase in demand for the covered products and services.